Investigational drugs for alcohol use disorders: a review of preclinical data - PubMed (original) (raw)
Review
. 2018 May;27(5):459-474.
doi: 10.1080/13543784.2018.1472763. Epub 2018 May 10.
Affiliations
- PMID: 29723484
- DOI: 10.1080/13543784.2018.1472763
Review
Investigational drugs for alcohol use disorders: a review of preclinical data
Sarah S Ch'Ng et al. Expert Opin Investig Drugs. 2018 May.
Abstract
Introduction: Alcohol use disorders (AUDs) are one of the leading causes of preventable death in the developed world. In the U.S., only three FDA-approved pharmacotherapies for AUDs currently exist, but at a population level they display poor efficacy, low compliance rates, and adverse side effects. Therefore, identifying novel neurobiological targets for pharmacological treatment of AUDs is of urgent concern.
Areas covered: We discuss recent preclinical data on investigational drugs that have been assessed for their therapeutic potential in AUDs. We focus on three neurobiological domains underlying AUDs: neuropeptide systems, neuroinflammatory/neuroimmune mediators, and epigenetic modifications. We iterate the therapeutic potential of ghrelin receptor antagonists, oxytocin, neurokinin 1 receptor antagonists, and glucagon-like peptide-1 receptor agonists. In the context of neuroinflammatory/neuroimmune modulators, we draw attention to P2X4 receptor positive allosteric modulators and phosphodiesterase inhibitors. Finally, we highlight the prospects of histone deacetylase inhibitors and DNA methyltransferases that modulate the dysregulated epigenetic landscape in alcohol dependence.
Expert opinion: We propose that several of the compounds discussed may be suitable to be repurposed for AUD treatment. We allude to the possibility of combined pharmacotherapy for AUDs and anticipate the efforts that must be enacted to advance the field of personalised medicine for the treatment of this devastating condition.
Keywords: Alcohol use disorders; epigenetics; neuroinflammation; neuropeptides; pharmacotherapies; preclinical.
Similar articles
- Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders.
Walker LC, Lawrence AJ. Walker LC, et al. Expert Opin Investig Drugs. 2018 Jul 27:1-14. doi: 10.1080/13543784.2018.1502269. Online ahead of print. Expert Opin Investig Drugs. 2018. PMID: 30019949 - Advancing Pharmacotherapy Development from Preclinical Animal Studies.
Egli M. Egli M. Handb Exp Pharmacol. 2018;248:537-578. doi: 10.1007/164_2017_85. Handb Exp Pharmacol. 2018. PMID: 29374834 - Investigational drugs under development for the treatment of PTSD.
Ragen BJ, Seidel J, Chollak C, Pietrzak RH, Neumeister A. Ragen BJ, et al. Expert Opin Investig Drugs. 2015 May;24(5):659-72. doi: 10.1517/13543784.2015.1020109. Epub 2015 Mar 14. Expert Opin Investig Drugs. 2015. PMID: 25773140 Review. - Pharmacotherapy of alcoholism - an update on approved and off-label medications.
Soyka M, Müller CA. Soyka M, et al. Expert Opin Pharmacother. 2017 Aug;18(12):1187-1199. doi: 10.1080/14656566.2017.1349098. Epub 2017 Jul 24. Expert Opin Pharmacother. 2017. PMID: 28658981 Review. - Emerging drugs for panic disorder.
Perna G, Guerriero G, Caldirola D. Perna G, et al. Expert Opin Emerg Drugs. 2011 Dec;16(4):631-45. doi: 10.1517/14728214.2011.628313. Epub 2011 Oct 17. Expert Opin Emerg Drugs. 2011. PMID: 21999303 Review.
Cited by
- Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain.
Aranda J, Fernández-Arjona MDM, Alén F, Rivera P, Rubio L, Smith-Fernández I, Pavón FJ, Serrano A, Serrano-Castro PJ, Rodríguez de Fonseca F, Suárez J. Aranda J, et al. Brain Struct Funct. 2021 Sep;226(7):2243-2264. doi: 10.1007/s00429-021-02321-9. Epub 2021 Jul 8. Brain Struct Funct. 2021. PMID: 34236532 Free PMC article. - Blood vessel remodeling in the cerebral cortex induced by binge alcohol intake in mice.
Hasegawa H, Tanaka T, Kondo M, Teramoto K, Nakayama K, Hwang GW. Hasegawa H, et al. Toxicol Res. 2022 Dec 21;39(1):169-177. doi: 10.1007/s43188-022-00164-y. eCollection 2023 Jan. Toxicol Res. 2022. PMID: 36726835 Free PMC article. - Alcohol Intoxication and Cognition: Implications on Mechanisms and Therapeutic Strategies.
Jacob A, Wang P. Jacob A, et al. Front Neurosci. 2020 Feb 12;14:102. doi: 10.3389/fnins.2020.00102. eCollection 2020. Front Neurosci. 2020. PMID: 32116535 Free PMC article. Review. - Advances in the science and treatment of alcohol use disorder.
Witkiewitz K, Litten RZ, Leggio L. Witkiewitz K, et al. Sci Adv. 2019 Sep 25;5(9):eaax4043. doi: 10.1126/sciadv.aax4043. eCollection 2019 Sep. Sci Adv. 2019. PMID: 31579824 Free PMC article. Review. - Neurochemical Evidence of Preclinical and Clinical Reports on Target-Based Therapy in Alcohol Used Disorder.
Prajapati SK, Bhaseen S, Krishnamurthy S, Sahu AN. Prajapati SK, et al. Neurochem Res. 2020 Feb;45(2):491-507. doi: 10.1007/s11064-019-02944-9. Epub 2020 Jan 2. Neurochem Res. 2020. PMID: 31898084 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical